以完全控制为目标的哮喘管理2.ppt

* * Asthma quality of life can be measured by either generic or disease-specific questionnaires. For GOAL, the well known, disease-specific Asthma Quality of Life Questionnaire (AQLQ) was used. This validated scientific tool contains 32 questions over four different sections – activity limitations, asthma symptoms, emotional functioning and exposure to environmental stimuli. The overall score is the mean score of the four domains and each is scored on a 7-point scale from 1 (severe impairment) to 7 (no impairment). Notes. * Distribution of mean overall AQLQ values: AQLQ score: % /=1 - 2 1% /=2 - 3 7% /=3 - 4 22% /=4 - 5 35% /=5 - 6 27% /=6 - 7 8% 7 0% The majority of patients randomised to treatment showed considerable impairment in baseline quality of life, though there was a wide range of scores. These results suggest that there is much room for improving both control and Quality of Life in asthma, which is being investigated in the GOAL study. * Distribution of mean overall AQLQ values: AQLQ score: % /=1 - 2 1% /=2 - 3 7% /=3 - 4 22% /=4 - 5 35% /=5 - 6 27% /=6 - 7 8% 7 0% The majority of patients randomised to treatment showed considerable impairment in baseline quality of life, though there was a wide range of scores. These results suggest that there is much room for improving both control and Quality of Life in asthma, which is being investigated in the GOAL study. * Aiming for Total Control reduced the incidence of all exacerbations during the 52 weeks of the study, in all three strata. For all patients in all strata, there was a reduction in the incidence of exacerbations, regardless of whether they received monotherapy or combination therapy. However, the decrease was significantly larger in patients receiving Seretide across all three strata. This graph illustrates the reduction in the incidence of exacerbations from baseline and clearly shows the greater efficacy of Seretide, compared with ICS monotherapy with FP, in reducing the risk